Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014 Sep; 16(9):1257-69.

View in: PubMed

subject areas

Antigens, CD19
Cancer Vaccines
Cell Line, Tumor
Cell Proliferation
Culture Media, Serum-Free
Cytotoxicity, Immunologic
DNA Transposable Elements
Drug Resistance, Neoplasm
Genetic Engineering
Genetic Vectors
Humans
Immunotherapy, Adoptive
Interleukin-15
Interleukin-2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutation
Protein Kinase Inhibitors
Receptors, Antigen, T-Cell
Recombinant Fusion Proteins
T-Lymphocytes
TNF-Related Apoptosis-Inducing Ligand
Up-Regulation

authors with profiles

CLIONA ROONEY